Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Thankfully, the best luxury Advent calendars make it simple to surprise my friends and family members during the holidays, since the calendars contain a range of elevated, thoughtful beauty finds ...

For those looking to buy Zepbound online, our team of experts vetted the best places to obtain the prescription-only weight loss drug. Plus, learn more about shortages, drug effectiveness ...

The 35-year-old mom is one of many patients taking a compounded version of tirzepatide produced by a pharmacy while Eli Lilly's brand-name versions, Zepbound and Mounjaro, have been in short supply.

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...